Login
Greenland Mines Ltd logo

Greenland Mines Ltd

greenlandmines.com

What Do They Do?

Develops medicines for cancer, cardiovascular and neurodegenerative diseases, including generic drugs, biosimilars and Klotho gene therapies. Also develops and mines critical and precious minerals.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
Net income
▼ −10% (Loss)
vs −$4.1M in Q2 FY2025
  • Sep 4, 2026 Acquired the Sarfartoq mineral project through a merger The acquisition indirectly transferred the Greenland mineral license to the company.
  • Jun 29, 2026 Replaced its independent accounting firm Simon & Edward took over audit services previously provided by BCRG.

From blank-check company to operating businesses The older report describes a blank-check company seeking a business combination, focused on carbon-neutral and energy-storage industries. The latest report describes medicine development and an acquisition that expands operations into critical- and precious-mineral development and mining.

Who Do They Compete With?

Competes with Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Biogen, AstraZeneca, Teva Pharmaceutical Industries, Klothea BIO, Klotho Therapeutics, Klogenix, Amgen, Celltrion Healthcare, Sandoz International, Unity Biotechnology, Jocasta Therapeutics, Mylan, and Reliance Life Sciences

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support